Book a Meeting

Non-Fucosylated Anti-Human EGFR (RO5083945) Therapeutic Antibody (CAT#: BioBet-1829ZP) Datasheet

Target
EGFR
Isotype
IgG1
Description
Non-Fucosylated Anti-Human EGFR (RO5083945) is a glycosylation-modified therapeutic biobetter antibody.
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced EGFR antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
EGFR
Full Name
epidermal growth factor receptor
Background
The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer.
Alternative Names
EGFR; epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog
Gene ID
1956
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
RO5083945 (GA201)
Host
Humanized
Species Reactivity
Human
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.

Related Products

Non-fucosylated Anti-Human EGFR (Tomuzotuximab) Therapeutic Antibody (CAT#: BioBet-202ZP)
BetterBet™ Anti-EGFR Half-Life Extended Antibody (CAT#: AES-0622-ZP1001)
Non-fucosylated Anti-Human EGFR (Matuzumab) Therapeutic Antibody (CAT#: BioBet-201ZP)
Non-fucosylated Anti-Human EGFR (Modotuximab) Therapeutic Antibody (CAT#: BioBet-206ZP)
Highly Galactosylated Anti-EGFR (Modotuximab) Antibody (CAT#: BioBet-GA-206ZP)
Highly Galactosylated Anti-EGFR (Imgatuzumab) Antibody (CAT#: BioBet-GA-204ZP)
Highly Galactosylated Anti-EGFR (Zalutumumab) Antibody (CAT#: BioBet-GA-199ZP)
Non-fucosylated Anti-Human EGFR (Panitumumab) Therapeutic Antibody (CAT#: BioBet-198ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany